Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1038/s41467-017-00452-4 http://scihub22266oqcxt.onion/10.1038/s41467-017-00452-4 C5605714!5605714!28928360     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Nat+Commun 2017 ; 8 (ä): ä Nephropedia Template TP {{tp|p=28928360|t=2017. Tumor-associated B-cells induce tumor heterogeneity and therapy resistance |pdf=|usr=}}{{28928360}} gab.com Text Tumor-associated B-cells induce tumor heterogeneity and therapy resistance JO: Nat Commun http://www.kidney.de/pget.php?&tw=1&pmid=28928360 #FOAvip In melanoma, therapies with inhibitors to oncogenic BRAFV600E are highly effective but responses are often short-lived due to the emergence of drug-resistant tumor subpopulations. We describe here a mechanism of acquired drug resistance through the tumor microenvironment, which is mediated by human tumor-associated B cells. Human melanoma cells constitutively produce the growth factor FGF-2, which activates tumor-infiltrating B cells to produce the growth factor IGF-1. B-cell-derived IGF-1 is critical for resistance of melanomas to BRAF and MEK inhibitors due to emergence of heterogeneous subpopulations and activation of FGFR-3. Consistently, resistance of melanomas to BRAF and/or MEK inhibitors is associated with increased CD20 and IGF-1 transcript levels in tumors and IGF-1 expression in tumor-associated B cells. Furthermore, first clinical data from a pilot trial in therapy-resistant metastatic melanoma patients show anti-tumor activity through B-cell depletion by anti-CD20 antibody. Our findings establish a mechanism of acquired therapy resistance through tumor-associated B cells with important clinical implications. Twit Text FOAVip Tumor-associated B-cells induce tumor heterogeneity and therapy resistance ????Nat Commun http://www.kidney.de/pget.php?&tw=1&pmid=28928360 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=28928360 #FOAvip English Wikipedia <ref>{{Cite pmid|28928360}}</ref> Tumor-associated B-cells induce tumor heterogeneity and therapy resistance #MMPMID28928360 Somasundaram R; Zhang G; Fukunaga-Kalabis M; Perego M; Krepler C; Xu X; Wagner C; Hristova D; Zhang J; Tian T; Wei Z; Liu Q; Garg K; Griss J; Hards R; Maurer M; Hafner C; Mayerhöfer M; Karanikas G; Jalili A; Bauer-Pohl V; Weihsengruber F; Rappersberger K; Koller J; Lang R; Hudgens C; Chen G; Tetzlaff M; Wu L; Frederick DT; Scolyer RA; Long GV; Damle M; Ellingsworth C; Grinman L; Choi H; Gavin BJ; Dunagin M; Raj A; Scholler N; Gross L; Beqiri M; Bennett K; Watson I; Schaider H; Davies MA; Wargo J; Czerniecki BJ; Schuchter L; Herlyn D; Flaherty K; Herlyn M; Wagner SN Nat Commun 2017[]; 8 (ä): ä PMID28928360show ga In melanoma, therapies with inhibitors to oncogenic BRAFV600E are highly effective but responses are often short-lived due to the emergence of drug-resistant tumor subpopulations. We describe here a mechanism of acquired drug resistance through the tumor microenvironment, which is mediated by human tumor-associated B cells. Human melanoma cells constitutively produce the growth factor FGF-2, which activates tumor-infiltrating B cells to produce the growth factor IGF-1. B-cell-derived IGF-1 is critical for resistance of melanomas to BRAF and MEK inhibitors due to emergence of heterogeneous subpopulations and activation of FGFR-3. Consistently, resistance of melanomas to BRAF and/or MEK inhibitors is associated with increased CD20 and IGF-1 transcript levels in tumors and IGF-1 expression in tumor-associated B cells. Furthermore, first clinical data from a pilot trial in therapy-resistant metastatic melanoma patients show anti-tumor activity through B-cell depletion by anti-CD20 antibody. Our findings establish a mechanism of acquired therapy resistance through tumor-associated B cells with important clinical implications. äTumor-associated B-cells induce tumor heterogeneity and therapy resist(epmc).pdf DeepDyve Pubget Overpricing